Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.76 |
| ▸ | SELP | P16109 | 2/20 | 0.63 |
| ▸ | SELL | P14151 | 1/20 | 0.63 |
| ▸ | MAG | P20916 | 9/20 | 0.62 |
| ▸ | SELE | P16581 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390293 | 1.00 | SIGLEC7 (0.76) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL29732821 | 1.00 | SIGLEC7 (0.76) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL30650364 | 0.98 | SIGLEC7 (0.76) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700276 | 0.98 | SIGLEC7 (0.74) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700681 | 0.97 | SIGLEC7 (0.75) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700314 | 0.97 | SIGLEC7 (0.73) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700344 | 0.97 | SIGLEC7 (0.75) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31179876 | 0.97 | SIGLEC7 (0.73) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700290 | 0.97 | SIGLEC7 (0.75) | SIGLEC7SELPSELLMAGSELE | |
| SCHEMBL31700527 | 0.97 | SIGLEC7 (0.73) | SIGLEC7SELPSELLMAGSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098074-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2026-04-09 | — | — | US | claimed |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | ANGELES THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20250327807-A1 | NON-RADIOACTIVE CYTOTOXICITY ASSAYS | UNIV SOUTHERN CALIFORNIA (US) | 2025-10-23 | — | — | US | claimed |
| EP-4592310-A2 | NOVEL ANTIGEN BINDING DOMAINS AND SYNTHETIC ANTIGEN RECEPTORS INCORPORATING THE SAME | Angeles Therapeutics, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| EP-3516068-B1 | NON-RADIOACTIVE CYTOTOXICITY ASSAYS | UNIV SOUTHERN CALIFORNIA (US) | 2025-04-23 | — | — | EP | claimed |
| US-20250051797-A1 | ENGINEERED VIRAL PARTICLES AND USES OF THE SAME | INTERIUS BIOTHERAPEUTICS, INC. | 2025-02-13 | — | — | US | claimed |
| US-12196759-B2 | Non-radioactive cytotoxicity assays | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-01-14 | — | — | US | claimed |
| US-12128069-B2 | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-10-29 | — | — | US | claimed |
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | THE BROAD INSTITUTE, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-20240166755-A1 | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | UNIV SOUTHERN CALIFORNIA (US) | 2024-05-23 | — | — | US | claimed |
| WO-2024092508-A1 | USE OF MESENCHYMAL STEM CELL | 卡瑞济(北京)生命科技有限公司 | 2024-05-10 | — | — | WO | claimed |
| US-20230312677-A1 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | NOVARTIS AG (CH) | 2023-10-05 | — | — | US | claimed |
| US-20230293688-A1 | FUSOGENIC RHABDOVIRUS GLYCOPROTEINS AND USES THEREOF | INTERIUS BIOTHERAPEUTICS, INC. | 2023-09-21 | — | — | US | claimed |
| US-11535662-B2 | CD28 compositions and methods for chimeric antigen receptor therapy | NOVARTIS AG (CH) | 2022-12-27 | — | — | US | claimed |
| EP-3119423-B1 | TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2022-12-14 | — | — | EP | claimed |
| US-20220364125-A1 | GENOME ENGINEERING THE HUMAN IMMUNOGLOBULIN LOCUS TO EXPRESS RECOMBINANT BINDING DOMAIN MOLECULES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-11-17 | — | — | US | claimed |
| EP-4043485-A1 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | Novartis AG (CH) | 2022-08-17 | — | — | EP | claimed |
| WO-2022125590-A1 | A SYNTHETIC CIRCUIT FOR CELLULAR MULTISTABILITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-16 | — | — | WO | claimed |
| US-11307205-B2 | Non-radioactive cytotoxicity assays | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-04-19 | — | — | US | claimed |
| US-20220047677-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2022-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12128069-B2 | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker | PRKCA, PRKCH, PRKCB | SIGLEC7 644/4885SELP 2536/4885SELL 1856/4885 |
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | KLRK1, CD47, FCGR3B | SIGLEC7 14/4885SELP 296/4885SELL 145/4885 |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | NFRKB, NFATC1, NFKBIA | SIGLEC7 1202/4885SELP 557/4885SELL 330/4885 |
| US-20260098074-A1 | IMMUNE CELL FUNCTION | IL15, IL15RA, ICOS | SIGLEC7 465/4885SELP 930/4885SELL 107/4885 |
| US-20230312677-A1 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | ICOS, CD47, CD40 | SIGLEC7 149/4885SELP 556/4885SELL 222/4885 |
| US-11535662-B2 | CD28 compositions and methods for chimeric antigen receptor therapy | ICOS, CD47, CD40 | SIGLEC7 149/4885SELP 556/4885SELL 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.